Analysis of Subjects With Specific Adverse Events
(Incidence > 10 Subjects in One or More Treatment Groups)
ASaT

	Placebo		Drug High Dose		Drug Low Dose	
	n	(%)	n	(%)	n	(%)
APPLICATION SITE DERMATITIS	5	7.25	7	8.86	9	11.69
APPLICATION SITE ERYTHEMA	0	0	15	18.99	12	15.58
APPLICATION SITE IRRITATION	0	0	9	11.39	9	11.69
APPLICATION SITE PRURITUS	6	8.7	22	27.85	22	28.57
APPLICATION SITE VESICLES	0	0	6	7.59	0	0
BLISTER	0	0	0	0	5	6.49
COUGH	0	0	5	6.33	6	7.79
DIARRHOEA	9	13.04	0	0	5	6.49
DIZZINESS	0	0	12	15.19	8	10.39
ERYTHEMA	9	13.04	14	17.72	15	19.48
FATIGUE	0	0	5	6.33	5	6.49
HEADACHE	7	10.14	6	7.59	0	0
HYPERHIDROSIS	0	0	8	10.13	0	0
NASOPHARYNGITIS	0	0	6	7.59	0	0
NAUSEA	0	0	6	7.59	0	0
PRURITUS	8	11.59	26	32.91	23	29.87

Analysis of Subjects With Specific Adverse Events
(Incidence > 10 Subjects in One or More Treatment Groups)
ASaT

	Placebo		Drug High Dose		Drug Low Dose	
	n	(%)	n	(%)	n	(%)
RASH	5	7.25	11	13.92	13	16.88
SINUS BRADYCARDIA	0	0	8	10.13	7	9.09
SKIN IRRITATION	0	0	5	6.33	6	7.79
UPPER RESPIRATORY TRACT INFECTION	6	8.7	0	0	0	0
VOMITING	0	0	7	8.86	0	0

[†]This is footnote 1
This is footnote 2

Source: xxx